asco.org3d
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org3d
T-cell redirected bispecific antibodies in relapsed and refractory multiple myeloma: A systematic review and meta-analysis.
NR- not reported NR*- not reached Clinical outcome data with use of bispecific antibodies.
asco.org3d
Feasibility of pharmacist co-management for patients prescribed oral anticancer therapy for gastrointestinal cancers.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
Chemotherapy for metastatic colon cancer: Effect on survival when the dose is reduced due to side effects.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
Combination immunotherapy selection for non-PD-1 axis driven tumors.
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...
asco.org4d
ASCO's Advocacy Toolkit
The Association for Clinical Oncology (ASCO) offers multiple ways for you and your colleagues to engage with policymakers and educate them on ASCO’s advocacy priorities, while leveraging your insights ...
asco.org4d
Evolving patterns of transplant strategies for mantle cell lymphoma in the era of BTK inhibitors and CAR-T therapy.
83.3% (n=25) vs 6.7% (n=2) vs 10% (n=3) 21.8% (n=8) vs 15.6% (n=2) vs 59.3% (n=19) 44.4% (n=4) vs 11.1% (n=1) vs 44.4% (n=4) <0.001 ...